PP405 is discussed as a potential treatment for hair loss, with excitement about its promise but skepticism about its current effectiveness. Users mention combining it with treatments like minoxidil, finasteride, and microneedling, but emphasize it is not a cure.
The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.
Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.
Users discuss using GHK Cu and AHK Cu spray from Happy Soul Organics for hair loss, with some opting to make their own due to high costs. They also mention using treatments like finasteride, minoxidil, and dutasteride, noting some progress with hair growth.
The conversation is about hair loss treatments, specifically using finasteride, minoxidil, and biotin, with a focus on the effectiveness of Hims products. Users discuss the results, potential side effects, and the role of biotin in the treatment.
The conversation discusses hair loss, genetics, and treatments like Dutasteride. It highlights the influence of genetics on hair loss, noting that indigenous people are less prone to it.
The conversation is about a user experiencing positive hair regrowth results using 1mg of dutasteride, 10% minoxidil, and occasional microneedling, after unsatisfactory results with finasteride. Other users express interest in switching to dutasteride and share similar sentiments about finasteride.
Many users shared their experiences with finasteride and dutasteride for hair loss, with most reporting no significant side effects. Some users also discussed using oral minoxidil, noting improvements in hair thickness and density.
A 25-year-old is experiencing chronic telogen effluvium (TE) and androgenetic alopecia (AGA) after surgery, using finasteride, red light therapy, and supplements, and considering oral minoxidil despite heart concerns. They are unsure whether to start minoxidil before or after an upcoming surgery, which may trigger another hair shed.
Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.
Nemanja Gudelj likely uses finasteride and minoxidil alongside his hair transplant. Many believe medication is necessary for maintaining hair transplant results, though some claim success without it.
The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.
A user shared their positive experience with a 2200 graft FUE hair transplant at DiStefano Hair Restoration in Worcester, MA, praising Dr. Heinis and his staff for their care. The user is also using oral Dutasteride, topical Minoxidil, and vitamins D and B.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
Exploring a potential hair loss treatment using the enzyme AKR1C2 to locally reduce DHT levels. Challenges include enzyme delivery through the skin and high production costs, with gene therapy or stem cells suggested as future alternatives.
Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.
The conversation discusses various hair loss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.
The user shared a 2-month update after receiving 2023 hair grafts, noting improvements in hair thickness, density, and color after starting finasteride and minoxidil. They are still in the early recovery phase.
The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.
A user shared their success with 1mg daily finasteride, regrowing their crown hair significantly over 15 months without side effects. The user attributes their results to being a hyper responder and did not use minoxidil or other treatments.
The conversation discusses the role of NADPH in hair loss and the potential impact of creatine and B complex vitamins on hair shedding. The user theorizes that increasing NAD levels with B complex vitamins may reduce hair shedding, despite using finasteride and minoxidil for 9 months.
CB-03-01 is considered too costly and lacks a proper delivery method, making it less viable compared to RU58841, which has shown effectiveness with minimal side effects. Finasteride caused a drop in libido for one user.
Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.
Melatonin, gingko biloba, and biotin are effective for treating hair loss with good tolerability. Alternatives like dutasteride, minoxidil, and other peptides are also discussed.
Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It humorously questions the idea of placing a biodome on the scalp.
PP405 is in a phase 3 trial for hair loss treatment, with the study expected to run until June 2028. Minoxidil and finasteride remain key treatments, with hopes for PP405 to offer a new mechanism of action.